Observation of the clinical efficacy of gynecological Duanhongyin capsules in the treatment of abnormal uterine bleeding after placement of subcutaneous implanted contraceptive with pregnene
ZHU Jun
ZHANG Su-ying
FENG Jie
WU Di
YANG Yang
HUANG An-feng
JIANG Li-rong
LI Xiao-juan
HE Cha-ying
Abstract：Objective Observation of the clinical efficacy and safety of gynecological Duanhongyin capsules in the treatment of abnormal uterine bleeding after placement of subcutaneous implanted contraceptive with pregnene.Methods This study is a randomized controlled trial,using a numerical table method to randomly select 60 patients from the Family Planning Center of Hangzhou Obstetrics and Gynecology Hospital from August 2022 to November 2024 who experienced abnormal uterine bleeding after receiving subcutaneous implantation of etoposide contraceptive,divided into a treatment group and a control group,with 30 cases in each group.The control group did not receive any medication intervention treatment except for counseling and comfort.The research group added gynecological Duanhongyin capsules for treatment.Observe the effective rate of two treatment groups,the duration of abnormal uterine bleeding and vaginal bleeding,the recurrence rate of abnormal uterine bleeding,the continuation rate of subcutaneous implant contraception,hormone levels in the body,and endometrial thickness,and conduct safety evaluation.Results The total effective rate of clinical treatment in the research group was 86.67％,significantly higher than the control group's 3.33％(P＜0.001);The median number of vaginal bleeding days in the first month after medication was 5.5(4.0,10.0),the median number of vaginal bleeding days in the second month after medication was 5.0(4.0,10.0),and the median number of vaginal bleeding days in the third month after medication was 5.0(4.0,8.5),all of which showed statistically significant differences compared to the control group(P＜0.001).The recurrence rate of abnormal uterine bleeding after 3 months of observation and treatment was 20.00％in the study group(100.00％in the control group),and the follow-up removal rate was only 36.67％in the study group(96.67％in the control group),with significant statistical differences(all P＜0.001).The incidence of complications and other adverse events was similar between the study group and the control group,with no statistically significant differences(all P＞0.05).Conclusion Gynecological Duanhongyin capsules have shown significant clinical efficacy and medication safety in treating abnormal uterine bleeding caused by subcutaneous implantation of contraceptive agents.
Keywords：gynecological Duanhongyin capsulessubcutaneous implantation of contraceptive based on pregneneabnormal uterine bleeding
Publication Date：2025-08-02
Online Publishing Date：2025-09-30(First online date of this platform, not the publication date of the document)
Pages：5( 847-851 )